Skip to main content
SpringerLink
Log in

Chemotherapy for advanced malignant melanoma

  • Reviews
  • Published:
International Journal of Clinical and Laboratory Research

Summary

Systemic chemotherapy for the treatment of metastatic melanoma remains disappointing. Nor new single agent has demonstrated promising results. The combination of cisplatin, decarbazine, carmustine, and tamoxifen appears to be one of the most active regimens with an overall response rate approaching 50%. In some patients, responses have been durable and exceed 3 years. Sequential small phase II trials suggest that tamoxifen is an important component in this combination. The efficacy of the combination of hormonal and chemotherapy, however, needs to be corroborated in a large multicenter phase II trial. In addition, further laboratory and clinical studies are needed to evaluate the role of tamoxifen. Biological response modifiers, such as interleukin-2 and α-interferon, have limited activity as single agents, but in combination with cytotoxic agents show some promise and merit further evaluation. Future research should focus on the development of more effective agents, and on the use of aggressive adjuvant and neoadjuvant chemotherapy in high-risk patients with locally advanced disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adlaka A, Robinson WA, Gonzalez R, et al., Combination chemotherapy and tamoxifen in the treatment of disseminated malignant melanoma. Proceedings of the 2nd International Conference of Melanoma, 16–19 Oct, Venice, pp 401, 1990

  2. Atkins M, Demchac P, Mier J, et al. Phase II study alternating interleukin-2 (IL-2) and cisplatin (CDDP) with WR-2721 in metastatic melanoma. Proc Am Soc. Clin Oncol 9:186, 1990

    Google Scholar 

  3. Berd D, McLaughlin CJ, Hart E, Wiebe VJ, Mastrangelo MJ, Bellet RE, De Gregorio MW, Short course, high-dose tamoxifen (TAM) with cytotoxic chemotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 10:291, 1991

    Google Scholar 

  4. Boring CC, Squires TS, Tong T, Cancer statistics. CA 41:19, 1991

    PubMed  CAS  Google Scholar 

  5. Breier S, Pensel R, Roffe C, et al., High-dose DTIC with recombinant human interferon alpha-2b (rhIFN2b) for the treatment of metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol 9:281, 1990

    Google Scholar 

  6. Buzaid AC, Murren J, Durivage HJ, High-dose cisplatin plus WR-2721 in a split course day 1, day 8 in metastatic melanoma: a phase II study. Am J Clin Oncol 14:203, 1991

    PubMed  CAS  Google Scholar 

  7. Buzaid AC, Murren JR, Durivage HJ, High-dose cisplatin plus DTIC and tamoxifen in the treatment of metastatic melanoma. Cancer 68:1238, 1991

    Article  PubMed  CAS  Google Scholar 

  8. Ciobanu N, Dutcher J, Gucalp R, et al. High-dose chemotherapy with autologous bone marrow transplantation (ABMT) for malignant melanoma after failure of interleukin-2 (IL-2) and lymphokine activated killer (LAK) cells. Proc Am Soc Clin Oncol 8:281, 1989

    Google Scholar 

  9. Cocconi G, Bella M, Calabresi F, et al., DTIC vs DTIC plus tamoxifen in metastatic malignant melanoma. Proc Am Soc Clin Oncol 9:278, 1990

    Google Scholar 

  10. Del Prete SA, Maurer LH, O'Donnell J et al., Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403, 1984

    PubMed  Google Scholar 

  11. Dillman RO, Oldham RK, Barth NM, et al., Recombinant interleukin-2 and adoptive immunotherapy with dacarbazine therapy in melanoma. A National Biotherapy Study Group. J Natl Cancer Inst 82:1345, 1990

    Article  PubMed  CAS  Google Scholar 

  12. Eder JP, Antman K, Elias A, et al., Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 80:1221, 1988

    Article  PubMed  CAS  Google Scholar 

  13. Einzig A, Trump DL, Sasloff J, Phase II pilot study of taxol in patients with malignant melanoma. Proc Am Soc Clin Oncol 7:249, 1988

    Google Scholar 

  14. Flaherty LE, Redman BG, Chabot GC, et al., A phase I–II study of dacarbazine in combination with outpatient interleukin-2 in metastatic melanoma. Cancer 65:2471, 1990

    Article  PubMed  CAS  Google Scholar 

  15. Glover D, Glick J, Weiler, et al., High dose cisplatinum (DDP) and WR-2721 (WR) in metastatic melanoma. Proc Am Soc Clin Oncol 7:247, 1988

    Google Scholar 

  16. Hoffman J, Doppler W, Jakob A, et al., Enhancement of the antiproliferative effect of cis-dichlorodiammineplatinum (II) and nitrogen mustard by inhibitors of protein kinase C Int J Cancer 42:382, 1988

    Article  Google Scholar 

  17. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66:1873, 1990

    Article  PubMed  CAS  Google Scholar 

  18. Lazarus HM, Herzig RH, Wolff SN, et al., Treatment of metastatic melanoma with intensive melphalan and autologous bone marrow transplantation. Cancer Treat Rep 69:473, 1985

    PubMed  CAS  Google Scholar 

  19. Legha S, Ring S, Balch CM, et al. Induction chemotherapy for the treatment of patients with stage II malignant melanoma. In: Salmon S (ed) Adjuvant therapy of cancer. VI. Saunders, Philadelphia, pp 586–592, 1990

    Google Scholar 

  20. Legha SS, Ring S, Papadopoulos N, et al., A phase II trial of taxol in metastatic melanoma. Cancer 65:2478, 1990

    Article  PubMed  CAS  Google Scholar 

  21. Legha S, Ring S, Plager C, Papadopoulos N, Gutterman J, Benjamin RS, Biochemotherapy using interleukin-2 (IL-2) +interferon alfa-2a (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in advanced melanoma. Proc Am Soc Clin Oncol 10:293, 1991

    Google Scholar 

  22. LoRusso PM, Polin L, Auckerman SL, et al., Antitumor efficacy of interleukin-2 alone and in combination with chemotherapeutic agents in murine syngeneic solid tumor systems. Proc Am Assoc Cancer Res 30: 614, 1989

    Google Scholar 

  23. Margolain K, Doroshow J, Akman S, et al., Treatment (Rx) of advanced melanoma with cisdiamminedichloroplatinum (CDDP) and alpha interferon (IFN). Proc Am Soc clin Oncol 9:277, 1990

    Google Scholar 

  24. Mastrangelo MJ, Bellet RE, Berd D, Aggressive chemotherapy for melanoma. PPO updates 5: 1, 1991

    Google Scholar 

  25. McClay EF, Mastrangelo MJ, Bellet RE, et al., Combination chemo/hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465, 1987

    PubMed  CAS  Google Scholar 

  26. McClay EF, Mastrangelo MJ, Bellet R, et al., An effective chemo/hormonal therapy regimen for the treatment of disseminated malignant melanoma. Proc Am Soc Clin Oncol 8:282, 1989

    Google Scholar 

  27. McClay EF, Mastrangelo MJ, Sprandio JD, et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63:1292, 1989

    Article  PubMed  CAS  Google Scholar 

  28. McClay EF, Albright K, Jones J, Christen R, Howell SB, Modulation of cisplatin (DDP) sensitivity by tamoxifen (TAM) in human malignant melanoma. Proc Am Soc Clin Oncol 10:291, 1991

    Google Scholar 

  29. McElwain TJ, Hedley DW, Gordon MY, et al., High-dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol 7 [Suppl 5]: 360, 1979

    PubMed  Google Scholar 

  30. Murren J, Buzaid AC, The role of interferons in the treatment of malignant neoplasms. Yale J Biol Med 62:271, 1989

    PubMed  CAS  Google Scholar 

  31. Murren J, DeRosa W, Durivage HJ, et al., High-dose cisplatin plus DTIC in the treatment of metastatic melanoma. Cancer 67:1514, 1991

    Article  PubMed  CAS  Google Scholar 

  32. Richner J, Cerny TH, Joss RA, et al., A phase II study of continuous subcutaneous alpha-2b interferon (IFN) combined with cisplatin (CDDP) in advanced malignant melanoma (MM). Proc Am Soc. Clin Oncol 9:280, 1990

    Google Scholar 

  33. Rosenberg SA, Adoptive cellular therapy in patients with advanced cancer. Biol Ther Cancer Updates 1:1, 1991

    Google Scholar 

  34. Slease RB, Benear JB, Selby GB, et al., High dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol 6:1314, 1988

    PubMed  CAS  Google Scholar 

  35. Steffens TA, Bajorin DF, Chapman PB, et al., A phase II trial of high-dose cisplatin and dacarbazine: lack of efficacy of high-dose cisplatin-based therapy for metastatic melanoma. Cancer 68:1230, 1991

    Article  PubMed  CAS  Google Scholar 

  36. Thatcher N, Lind M, Morgenstern G, et al., High-dose double alkylating agent chemotherapy with DTIC, melphalan or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer 63: 1296, 1989

    Article  PubMed  CAS  Google Scholar 

  37. Wiernik PH, Schwartz EL, Einzig A, et al., Phase I trial of taxol given as 24 hour infusion every 21 days: response observed in metastatic melanoma. J Clin Oncol 8:1232, 1987

    Google Scholar 

  38. Wolff SN, Herzig RH, Fay JW, et al., High-dose thiotepa with autologous bone marrow transplantation of metastatic malignant melanoma: results of phase I–II studies of the North American Bone Marrow Transplantation Group. J Clin Oncol 7:245, 1989

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Medical Oncology, Yale University School of Medicine, NSB-294, 333 Cedar Street, 06510, New Haven, CT, USA

    Antonio C. Buzaid & John Murren

Authors
  1. Antonio C. Buzaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Murren
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buzaid, A.C., Murren, J. Chemotherapy for advanced malignant melanoma. Int J Clin Lab Res 21, 205–209 (1992). https://doi.org/10.1007/BF02591647

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02591647

Key words

Search

Navigation